This study, published in the special issue of MDPI Pharmaceutics: Advances in Pharmacokinetics and Drug Interactions, explored drug-drug interactions (DDIs) and food effects for Bevurogant (BI 730357), a competitive antagonist of the retinoic acid-related orphan receptor γ (RORγ), investigated as an oral treatment for plaque psoriasis. The publication was co-authored by Dr. Tobias Kanacher, Assoc. Prof Dr. Erik Sjögren, and Dr. Elodie Plan, in collaboration with Dr. Ibrahim Ince (Head of PBPK working group, Senior Principal Scientist in Pharmacometrics) and colleagues at Boehringer Ingelheim. Medical writing by provided by Dr. Annika Eklund, Pharmetheus.